- MarketWatch•26 minutes ago
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about ...
- PR Newswire•3 days ago
The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Neurocrine also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $67.5 million aggregate principal amount of notes. The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable in cash semi-annually in arrears at a rate of 2.25% per annum.
- PR Newswire•4 days ago
SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable semiannually in arrears. The notes will be convertible in certain circumstances into cash, shares of Neurocrine's common stock, or a combination of cash and shares of Neurocrine's common stock, at Neurocrine's election.
NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||42.00 x 100|
|Ask||62.70 x 300|
|Day's Range||52.56 - 53.85|
|52 Week Range||37.35 - 55.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-32.76|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|